Your browser is no longer supported. Please, upgrade your browser.
Settings
ITRM Iterum Therapeutics plc daily Stock Chart
ITRM [NASD]
Iterum Therapeutics plc
Index- P/E- EPS (ttm)-7.09 Insider Own3.58% Shs Outstand14.72M Perf Week13.96%
Market Cap44.60M Forward P/E- EPS next Y-3.51 Insider Trans0.00% Shs Float14.34M Perf Month10.18%
Income-103.70M PEG- EPS next Q-1.70 Inst Own56.90% Short Float3.92% Perf Quarter40.28%
Sales0.30M P/S148.67 EPS this Y-139.70% Inst Trans-4.69% Short Ratio1.73 Perf Half Y-53.31%
Book/sh-0.21 P/B- EPS next Y51.30% ROA-134.20% Target Price10.25 Perf Year-49.50%
Cash/sh2.03 P/C1.49 EPS next 5Y- ROE-286.70% 52W Range1.68 - 9.30 Perf YTD-32.67%
Dividend- P/FCF- EPS past 5Y- ROI-89.90% 52W High-67.42% Beta-
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low80.36% ATR0.32
Employees48 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)57.82 Volatility10.72% 10.02%
OptionableNo Debt/Eq- EPS Q/Q-20.90% Profit Margin- Rel Volume0.16 Prev Close3.00
ShortableYes LT Debt/Eq- EarningsMar 23 BMO Payout- Avg Volume325.63K Price3.03
Recom2.60 SMA2016.70% SMA50-5.61% SMA200-38.97% Volume51,540 Change1.00%
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Feb-19-20 07:30AM  Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +10.96%
Jan-17-20 06:15AM  Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors GlobeNewswire -26.01%
Jan-03-20 03:15PM  Riding December's Momentum Into 2020 Benzinga
Dec-26-19 05:00PM  Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection GlobeNewswire
Dec-12-19 09:42AM  Iterum Down as Sulopenem Antibiotic Fails in Phase III Study Zacks -7.05%
Dec-11-19 07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga -35.67%
Dec-10-19 04:10PM  Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections GlobeNewswire +21.86%
Nov-30-19 10:18AM  Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ? Insider Monkey
Nov-18-19 07:30AM  Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection GlobeNewswire +5.97%
Nov-12-19 07:05PM  Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates Zacks +5.65%
04:30PM  Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
Nov-08-19 01:01PM  What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)? Simply Wall St. +12.11%
Nov-06-19 10:30AM  Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline Zacks -6.76%
Oct-01-19 10:07AM  Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-27-19 04:30PM  Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-09-19 03:24PM  If You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today Simply Wall St. -8.91%
Aug-14-19 08:15AM  Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates Zacks -11.04%
07:00AM  Iterum Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 10:30AM  Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-01-19 07:30AM  Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-10-19 12:13PM  Who Has Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares? Simply Wall St.
Jul-01-19 09:13AM  X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire -7.70%
Jun-21-19 07:30AM  Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019 GlobeNewswire
Jun-20-19 11:13AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-07-19 09:27AM  Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire -9.54%
May-14-19 07:00AM  Iterum Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-11-19 07:30AM  Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019 GlobeNewswire
Mar-28-19 09:00AM  Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade Zacks
08:27AM  Will Iterum Therapeutics Continue to Surge Higher? Zacks
Mar-25-19 07:00AM  Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +10.18%
Mar-19-19 07:00AM  Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation GlobeNewswire +23.21%
Feb-21-19 10:15AM  What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)? Simply Wall St.
Feb-19-19 07:30AM  Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference GlobeNewswire
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Dec-20-18 12:36PM  Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock? Simply Wall St. -8.71%
Nov-14-18 07:15AM  Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire -10.46%
Nov-05-18 04:05PM  Iterum Therapeutics plc to Participate in Investor Conferences in November and December GlobeNewswire
Oct-05-18 08:00AM  Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018 GlobeNewswire
Sep-25-18 04:05PM  Iterum to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -5.66%
Sep-20-18 08:00AM  Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018 GlobeNewswire -16.83%
Sep-18-18 08:00AM  Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections GlobeNewswire
Aug-14-18 07:30AM  Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Aug-09-18 04:05PM  Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections GlobeNewswire
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
08:00AM  Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem PR Newswire
May-25-18 12:51AM  [$$] Drugmaker Iterum Therapeutics Bags $80 Million in IPO The Wall Street Journal
May-24-18 08:15PM  Iterum Therapeutics Announces Pricing of Initial Public Offering PR Newswire
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.